Recursion Ebit from 2010 to 2026
| RXRX Stock | USD 4.20 0.11 2.69% |
EBIT | First Reported 2020-03-31 | Previous Quarter -171.4 M | Current Value -162.2 M | Quarterly Volatility 53 M |
Check Recursion Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Recursion Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 17.1 M, Interest Income of 19 M or Depreciation And Amortization of 44.1 M, as well as many indicators such as Price To Sales Ratio of 34.42, Dividend Yield of 0.0 or PTB Ratio of 1.69. Recursion financial statements analysis is a perfect complement when working with Recursion Pharmaceuticals Valuation or Volatility modules.
Recursion | Ebit | Build AI portfolio with Recursion Stock |
Latest Recursion Pharmaceuticals' Ebit Growth Pattern
Below is the plot of the Ebit of Recursion Pharmaceuticals over the last few years. It is Recursion Pharmaceuticals' EBIT historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Recursion Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Ebit | 10 Years Trend |
|
Ebit |
| Timeline |
Recursion Ebit Regression Statistics
| Arithmetic Mean | (161,242,887) | |
| Coefficient Of Variation | (92.10) | |
| Mean Deviation | 125,792,442 | |
| Median | (61,879,000) | |
| Standard Deviation | 148,512,662 | |
| Sample Variance | 22056T | |
| Range | 401.3M | |
| R-Value | (0.84) | |
| Mean Square Error | 6980.4T | |
| R-Squared | 0.70 | |
| Significance | 0.000026 | |
| Slope | (24,663,895) | |
| Total Sum of Squares | 352896.2T |
Recursion Ebit History
Other Fundumenentals of Recursion Pharmaceuticals
About Recursion Pharmaceuticals Financial Statements
Recursion Pharmaceuticals investors use historical fundamental indicators, such as Recursion Pharmaceuticals' Ebit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Recursion Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| EBIT | -416.9 M | -396 M | |
| EBITDA | -384 M | -364.8 M | |
| Ebt Per Ebit | 1.12 | 1.09 | |
| Ebit Per Revenue | (7.33) | (7.69) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| JBL | Jabil Circuit | |
| MRK | Merck Company | |
| AMGN | Amgen Inc |
Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.